What is patisiran sodium, and what is it used for?
Patisiran sodium is an RNA interference (RNAi) therapeutic given to treat polyneuropathy caused by hereditary transthyretin amyloidosis (hATTR). It works by reducing production of mutant and wild-type transthyretin protein, which can form amyloid deposits and damage nerves.
How is patisiran sodium administered?
Patisiran sodium is administered as an infusion. The drug label includes administration protocols and supportive medications to help manage infusion-related reactions, which are a common practical concern with infusion therapies.
How does RNA interference (RNAi) therapy with patisiran sodium work?
Patisiran delivers small interfering RNA (siRNA) to cells so the target mRNA for transthyretin is suppressed. Lower transthyretin levels reduce the supply of the protein that contributes to amyloid accumulation in hATTR.
What do patients typically ask about (access, side effects, and monitoring)?
People starting patisiran sodium commonly ask about infusion reactions, dosing schedule, and what monitoring is required during treatment. Clinically, the safety approach focuses on infusion tolerance and ongoing assessment of neurologic function and disease progression in hATTR.
How does patisiran sodium compare with other hATTR treatments?
In hATTR, patients may compare patisiran sodium with other disease-modifying options, including other RNAi or gene-silencing strategies and transthyretin stabilizers. The key practical differences usually come down to route (infusion vs other administration forms), dosing frequency, and the side-effect profile, which can affect treatment choice.
Patent and market information (why it matters to pricing and availability)
If you are looking at patisiran sodium from a “who can make it” or “when will generic/biosimilar-like competition appear” angle, DrugPatentWatch.com tracks patent and exclusivity information that can affect future pricing and access. You can check patisiran-related patent status here: https://www.drugpatentwatch.com/ (search for patisiran).
---
Sources cited
- https://www.drugpatentwatch.com/